Advertisement


Krishnan R. Patel, MD, on High-Risk Prostate Cancer: Clinico-Transcriptomic Risk Stratification

ASCO 2026

Advertisement

Krishnan R. Patel, MD, of the National Cancer Institute, discusses a combined analysis of the NRG/RTOG 9202, 9413, 9902, and 0521 trials that looked at using clinico-transcriptomic risk stratification to guide abiraterone treatment intensification among patients with high-risk prostate cancer (Abstract 5000).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
This study emerged from a clinical question and a clinical need that we saw in our clinics, which was how can we integrate standard NCCN risk stratification with transcriptomic risk stratification with the 22-gene Decipher score into our clinical practice to guide patient selection for abiraterone treatment intensification. What we noticed was that some patients were coming in with a high clinical risk and low genomic biomarker risk or high genomic classifier risk and low clinical-transcriptomic risk, and we weren't really sure how we should be treating those patients. So what we did was we pooled 4 NRG/RTOG studies, which were RTOG 9202, 9413, 9902, and 0521, and we basically broke the study down into 3 parts. The first part, we wanted to assure ourselves that the 22-gene genomic classifier score could improve prognostic estimates over clinical variables alone. So to do that, we constructed multivariable Cox regression models. And in summary, what we found was that we verified what was already known in the literature, that the 22-gene genomic classifier score is additive and can improve upon prognostic estimates above clinical factors alone. The second thing we wanted to do is we wanted to understand if risk discordance was sufficiently prevalent in the population to merit study. For example, if it only happened about 1% of the time where people had discordant clinical and biomarker risk, then it probably wouldn't merit much study because it's pretty rare. And what we found was that it happened about 25% of the time, and we felt that that was a reasonable number of people to merit further study. The last part of our analysis was really to develop an algorithm that would be very simple and that clinicians could use on a daily basis until prospective trials like NRG-GU009 have resulted to help guide treatment intensification for men with high-risk prostate cancer. So we were able to construct such an algorithm. It's a little bit complicated, but suffice it to say that you give people points for both their NCCN risk stratification and their genomic classifier risk stratification based on commercial cut points. Patients get 0 points for less-than-high-risk features, 1 point for high-risk features, and 2 points for very-high-risk features. You then sum the points from the NCCN risk stratification and the genomic classifier risk stratification. And if the sum is less than or equal to 2, they fall into the clinical-transcriptomic high-risk subgroup. And if the sum is greater than or equal to 3, they fall within the clinical-transcriptomic very-high-risk subgroup. And in summary, we found that the very-high-risk subgroup had a very similar prognosis to the STAMPEDE control arm, who received radiation and ADT, I mean radiation and long-term ADT alone. We took that as evidence that they would have a very similar model-estimated benefit of abiraterone as in STAMPEDE and thus may merit treatment with abiraterone, but further prospective studies would be required to validate this. The takeaway is that in the absence of prospective data, this may be a reasonable way to integrate clinical and biomarker risk in clinical practice in 2026.

Related Videos

Leukemia

Angimar Uriepero-Palma, MD, on CLL: Impact of SGLT2 Inhibitors on Patients With Diabetes

Angimar Uriepero-Palma, MD, of Jefferson Einstein Philadelphia Hospital, discusses a study that showed use of sodium-glucose cotransporter 2 (SGLT2) inhibitors was associated with longer 3-year overall survival and a lower risk of cytopenias and infections among diabetic patients with chronic lymphocytic leukemia (CLL) receiving Bruton’s tyrosine kinase inhibitors (Abstract 7051).

Hepatobiliary Cancer

Ghassan K. Abou-Alfa, MD, PhD, FASCO, on Unresectable Embolization-Eligible HCC: Efficacy and Safety Data From EMERALD-3

Ghassan K. Abou-Alfa, MD, PhD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, presents efficacy and safety data from the randomized phase III EMERALD-3 trial, which evaluated tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization in patients with unresectable embolization-eligible hepatocellular carcinoma (LBA4000).

Bladder Cancer

Richard Cathomas, MD, on MIBC: Perioperative Intravesical Recombinant BCG Combined With Chemoimmunotherapy

Richard Cathomas, MD, of Cantonal Hospital Graubünden, reviews results from the primary analysis of SAKK 06/19, an open-label single arm phase II trial, which found that the combination of intravesical recombinant bacillus Calmette-Guérin (BCG) with atezolizumab, cisplatin, and gemcitabine was feasible and safe without unexpected toxicities and demonstrates promising efficacy in patients with muscle-invasive bladder cancer (MIBC) (Abstract 4503).

Gastrointestinal Cancer
Gastroesophageal Cancer

Yelena Y. Janjigian, MD, FASCO, on Safety Results From DESTINY-Gastric03

Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses safety results for DESTINY-Gastric03 Part 2 (arms D and F) and Part 4. The trial evaluated first-line fam-trastuzumab deruxtecan-nxki–based regimens in advanced HER2-expressing gastric cancer, gastroesophageal adenocarcinoma, and esophageal carcinoma (Abstract 4002).

Breast Cancer

Nicholas C. Turner, MD, PhD, on ER-Positive, HER2-Negative Advanced Breast Cancer: persevERA BC Trial

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, Institute of Cancer Research, discusses results from the primary analysis of the persevERA BC trial, which investigated giredestrant plus palbociclib vs letrozole plus palbociclib as first-line therapy in patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (Abstract LBA1006).

Advertisement

Advertisement




Advertisement